Ofatumumab for post-transplant lymphoproliferative disorder
| Autor: | Madhav Seshadri, Genevieve M. Crane, Usama Gergis |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.drug_class
medicine.medical_treatment Hematopoietic stem cell transplantation Ofatumumab Monoclonal antibody Post-transplant lymphoproliferative disorder Virus 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine immune system diseases hemic and lymphatic diseases medicine CD20 biology business.industry Hematology General Medicine medicine.disease surgical procedures operative Oncology chemistry 030220 oncology & carcinogenesis Immunology biology.protein Rituximab business Viral load 030215 immunology medicine.drug |
| Zdroj: | Hematology/Oncology and Stem Cell Therapy. |
| ISSN: | 1658-3876 |
| DOI: | 10.1016/j.hemonc.2020.04.004 |
| Popis: | Posttransplant lymphoproliferative disorder (PTLD) includes a range of abnormal lymphoid proliferation following solid organ or allogeneic hematopoietic stem cell transplantation (HSCT), often associated with Epstein-Barr virus (EBV) infection. Treatment generally incudes rituximab, a chimeric monoclonal antibody directed against CD20. Here we present a 56-year-old woman with EBV-associated PTLD following allogeneic HSCT who was intolerant of rituximab. The patient was instead treated with ofatumumab, a fully human monoclonal antibody directed against CD20, with significant response in EBV viral load and lymphadenopathy. Ofatumumab could represent an important treatment option for patients unable to tolerate rituximab. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|